PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|January 2, 2015
- Pharmaceutical Technology-01-02-2015
- Volume 39
- Issue 1
Supercritical Fluid Technologies HPR-Micro Reactor Offers Ergonomic Design
Supercritical Fluid Technologies’ HPR-Micro Reactor is a high-pressure reactor designed for small-batch reaction chemistry. It is well suited for research, process development, and screening applications for reagents, catalysts, and other essential materials when they aren’t readily available. The reactor comes with Stirred Iconel 718 Reactor Vessel in 10-mL, 25-mL, or 50-mL capacities, with operations up to 10,000 psi (689 Bar/68.9 MPa). An ergonomic design allows the reactor to be placed into a fume hood.
Optionally, a reagent injection manifold can be included to allow for the precise addition of reagents at any time during the reaction, with standard addition quantities of 2.0 mL, 1.0 mL, and 0.5 mL. The reactor is designed for use in “green” supercritical carbon dioxide including: catalytic studies, polymerization, hydrogenation, oxidation, isomerization, and dehydrogenation. All high-pressure components are ASME compliant with rupture disc assembly to increase safety.
Supercritical Fluid Technologies
Article DetailsPharmaceutical Technology
Vol. No. 1
Page: 14
Articles in this issue
almost 12 years ago
Value-Based Healthcare in the: United Kingdomalmost 12 years ago
Mitigating Risk for Single-Use Assemblies in Sterile Fillingalmost 12 years ago
Building a Barrier in Solid-Dosage Drug Packagingalmost 12 years ago
Using Tocophersolan for Drug Deliveryalmost 12 years ago
Industry Expert Q&A with Fred Miesowiczalmost 12 years ago
Innovative Excipients in Solid-Dosage Manufacturingalmost 12 years ago
Great Expectations from New European Commissionalmost 12 years ago
Analyzing Protein Aggregation in Biopharmaceuticalsalmost 12 years ago
Ross Charging Hopper Increases Efficiencyalmost 12 years ago
Standards Organizations UpdateRelated to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.